Page 28 - Read Online

injury: an emerging cause of iatrogenic organ damage. Am J Surg Gastroenterol Hepatol 2005;3:761-71.
Pathol 2009;33:963-75. 66. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW,
53. Kalinowski M, Dressler M, Konig A, El-Sheik M, Rinke A, Höffken Thakker RV, Caplin M, Delle Fave G, Kaltsas GA, Krenning EP,
H, Gress TM, Arnold R, Klose KJ, Wagner HJ. Selective internal Moss SF, Nilsson O, Rindi G, Salazar R, Ruszniewski P, Sundin
radiotherapy with Yttrium-90 microspheres for hepatic metastatic A. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol
neuroendocrine tumors: a prospective single center study. Digestion 2008;9:61-72.
2009;79:137-42. 67. Andreyev H, Scott-Mackie P, Cunningham D, Nicolson V, Norman
54. Van der Zwan WA, Bodei L, Mueller-Brand J, de Herder WW, Kvols AR, Badve SS, Iveson A, Nicolson MC. Phase II study of continuous
LK, Kwekkeboom DJ. GEPNETs update: Radionuclide therapy in infusion fluorouracil and interferon alfa-2b in the palliation of
neuroendocrine tumors. Eur J Endocrinol 2015;172:R1-8. malignant neuroendocrine tumors. J Clin Oncol 1995;13:1486-92.
55. Stoeltzing O, Loss M, Huber E, Gross V, Eilles C, Mueller-Brand 68. Eriksson B, Skogseid B, Lundqvist G, Wide L, Wilander E, Oberg
J, Schlitt HJ. Staged surgery with neoadjuvant 90Y-DOTATOC K. Medical treatment and long-term survival in a prospective
therapy for down-sizing synchronous bilobular hepatic metastases study of 84 patients with endocrine pancreatic tumors. Cancer
from a neuroendocrine pancreatic tumor. Langenbecks Arch Surg 1990;65:1883-90.
2010;395:185-92. 69. Dahan, L, Bonnetain F, Rougier P, Raoul JL, Gamelin E, Etienne
56. Kaemmerer D, Prasad V, Daffner W, Hörsch D, Klöppel G, PL, Cadiot G, Mitry E, Smith D, Cvitkovic F, Coudert B, Ricard
Hommann M, Baum RP. Neoadjuvant peptide receptor radionuclide F, Bedenne L, Seitz JF; Fédération Francophone de Cancérologie
therapy for an inoperable neuroendocrine pancreatic tumor. World J Digestive (FFCD); Digestive Tumors Group of the Fédération
Gastroenterol 2009;15:5867-70. Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Phase
57. Sowa-Staszczak A, Pach D, Chrzan R, Trofimiuk M, Stefańska A, III trial of chemotherapy using 5-fluorouracil and streptozotocin
Tomaszuk M, Kołodziej M, Mikołajczak R, Pawlak D, Hubalewska- compared with interferon alpha for advanced carcinoid tumors:
Dydejczyk A. Peptide receptor radionuclide therapy as a potential tool FNCLCC-FFCD 9710. Endocr Relat Cancer 2009;16:1351-61.
for neoadjuvant therapy in patients with inoperable neuroendocrine 70. Mirvis E, Mandair D, Garcia-Hernandez J, Mohmaduvesh M,
tumours (NETs). Eur J Nucl Med Mol Imaging 2011;38:1669-74. Toumpanakis C, Caplin M. Role of interferon-alpha in patients
58. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van with neuroendocrine tumors: a retrospective study. Anticancer Res
Essen M, Kooij PP, Feelders RA, van Aken MO, Krenning EP. 2014;34:6601-7.
Treatment with the radiolabeled somatostatin analog [177 Lu- 71. Dogliotti L, Tampellini M, Stivanello M, Gorzegno G, Fabiani L.
DOTA 0,Tyr3] octreotate: toxicity, efficacy, and survival. J Clin The clinical management of neuroendocrine tumors with long-acting
Oncol 2008;26:2124-30. repeatable (LAR) octreotide: comparison with standard subcutaneous
59. Strosberg J, Wolin E, Chasen B, Kulke M, Bushnell D, Caplin M, octreotide therapy. Ann Oncol 2001;12 Suppl 2:S105-9.
Baum RP, Mittra E, Hobday T, Hendifar A, Oberg K, Lopera Sierra 72. Rinke A, Müller HH, Schade, Brittinger C, Klose KJ, Barth P,
M, Ruszniewski P, Kwekkeboom D; On behalf of the NETTER-1 Wied M, Mayer C, Aminossadati B, Pape UF, Bläker M, Harder
study group. 177Lu-Dotatate significantly improves progression- J, Arnold C, Gress T, Arnold R; PROMID Study Group. Placebo-
free survival in patients with midgut neuroendocrine tumours: results controlled, double-blind, prospective, randomized study on the
of the Phase III NETTER-1 trial. 18th ECCO-40th ESMO- European effect of octreotide LAR in the control of tumor growth in patients
Cancer Congress 2015, 27 September 2015, abs 6LBA, Vienna. with metastatic neuroendocrine midgut tumors: a report from the
60. Kong G, Johnston V, Ramdave S, Lau E, Rischin D, Hicks RJ. High PROMID Study Group. J Clin Oncol 2009;27:4656-63.
administered activity In-111 octreotide therapy with concomitant 73. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková
radiosensitizing 5FU chemotherapy for treatment of neuroendocrine E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A,
tumors: preliminary experience. Cancer Biother Radiopharm Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators;
2009;24:527-33. Lanreotide in metastic enteropancreatic neuroendocrine tumors. N
61. Bison SM, Pool SE, Koelewijn SJ, van der Graaf LM, Groen HC, Engl J Med 2014;371:224-33.
Melis M, de Jong M. Peptide receptor radionuclide therapy (PRRT) 74. Cives M, Kunz PL, Morse B, Coppola D, Schell MJ, Campos T,
with [(177)Lu-DOTA(0),Tyr(3)]octreotate in combination with Nguyen PT, Nandoskar P, Khandelwal V, Strosberg JR. Phase II clinical
RAD001 treatment: further investigations on tumor metastasis and trial of pasireotide long-acting repeatable in patients with metastatic
response in the rat pancreatic CA20948 tumor model. EJNMMI neuroendocrine tumors. Endocr Relat Cancer 2015;22:1-9.
Res 2014;4:21. 75. Alonso-Gordoa T, Capdevila J, Grande E. GEP-NETs update:
62. Oberg K. Interferons in the management of neuroendocrine tumors Biotherapy for neuroendocrine tumours. Eur J Endocrinol
and their possible mechanism of action. Yale J Biol and Med 2015;172:R31-46.
1992;65:519-29. 76. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E,
63. Frank M, Klose KJ, Wied M, Ishaque N, Schade-Brittinger C, Arnold Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti
R. Combination therapy with octreotide and alpha-interferon: effect P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K;
on tumor growth in metastatic endocrine gastroenteropancreatic RAD001 in Advanced Neuroendocrine Tumors, Third Trial
tumors. Am J Gastroenterol 1999;94:1381-7. (RADIANT-3) Study Group. Everolimus for advanced pancreatic
64. Faiss S, Pape UF, Böhmig M, Dörffel Y, Mansmann U, Golder neuroendocrine tumors. N Engl J Med 2011;364:514-23.
W, Riecken EO, Wiedenmann B; International Lanreotide and 77. Briest F, Grabowski P. PI3K-AKT-mTOR-signaling and beyond:
Interferon Alfa Study Group. Prospective, randomized, multicenter the complex network in gastroentero-pancreatic neuroendocrine
trial on the antiproliferative effect of lanreotide, interferon alfa, neoplasms. Theranostics 2014;4:336-65.
and their combination for therapy of metastatic neuroendocrine 78. Capdevila J, Salazar R, Halperin I, Abad A, Yao JC. Innovations
gastroenteropancreatic tumors -- The International Lanreotide and therapy: mammalian target of rapamycin (mTOR) inhibitors for
Interferon Alfa Study Group. J Clin Oncol 2003;21:2689-96. the treatment of neuroendocrine tumors. Cancer Metastasis Rev
65. Arnold R, Rinke A, Klose K, Müller HH, Wied M, Zamzow 2011;30 Suppl 1:27-34.
K, Schmidt C, Schade-Brittinger C, Barth P, Moll R Koller 79. Chambers J, Reed N, Mansoor W, Ross P, Grossman A. Phase-3
M, Unterhalt M, Hiddemann W, Schmidt-Lauber M, Pavel M, randomized trial of everolimus (RAD001) vs. placebo in advanced
Arnold CN. Octreotide versus octreotide plus interferon-alpha in pancreatic NET (RADIANT-3). Regul Pept 2010;164:6-7.
endocrine gastroenteropancreatic tumors: a randomized trial. Clin 80. Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler
302
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 17, 2016 ¦